bioAffinity Tech Stock Price, News & Analysis

bioAffinity Technologies (NASDAQ: BIAF) has appointed Dr. Gordon Downie as its new Chief Medical Officer. Dr. Downie brings over 30 years of experience in pulmonary medicine, clinical research, and interventional pulmonology. He has authored more than 30 peer-reviewed publications focused on bronchoscopy, early lung cancer diagnosis, and medical device development.

Dr. Downie previously served as Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center. He holds a PhD in experimental pathology from SUNY Buffalo and an MD from Northwestern University. Notably, before his medical career, he was an Olympic bronze medalist in swimming at the 1976 Summer Olympics.

In his new role, Dr. Downie will focus on scaling CyPath® Lung, the company's noninvasive diagnostic for lung cancer, and expanding their diagnostic platform to additional diseases.

bioAffinity Technologies (NASDAQ: BIAF) announced the release of a white paper by Dr. Gordon Downie highlighting the real-world impact of CyPath® Lung, their noninvasive sputum-based test for early-stage lung cancer detection. The paper details four clinical cases where CyPath® Lung significantly influenced decision-making for patients with indeterminate pulmonary nodules.

Dr. Downie, Director of the Lung Nodule Clinic at Titus Regional Medical Center, demonstrated how the test helped in various scenarios, including cases with sub-8mm nodules, prior cancer history, post-COVID changes, and previous lung cancer diagnosis. The test serves as an adjuvant after CT and PET imaging, providing additional information about malignancy likelihood in lung nodules, where approximately 98% are benign.

bioAffinity Technologies (NASDAQ: BIAF) has completed a $3.25 million best efforts offering of securities. The offering included 10,156,250 shares of Common Stock (or pre-funded warrants) and warrants to purchase up to 15,234,375 shares of Common Stock (May 2025 Warrants) at a combined public offering price of $0.32 per share and accompanying warrant. WallachBeth Capital LLC served as the sole placement agent for this offering. The offering was conducted through a registration statement on Form S-1 that was previously filed and declared effective by the SEC.

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company developing noninvasive early-stage cancer detection tests, has closed a $3.25 million offering. The offering included 10,156,250 shares of Common Stock (or pre-funded warrants) at $0.32 per share, along with warrants to purchase up to 15,234,375 additional shares. WallachBeth Capital acted as the sole placement agent for this best efforts offering, which was conducted through a registration statement on Form S-1 previously declared effective by the SEC.

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company developing noninvasive early-stage cancer detection tests, has announced a $3.25 million offering through WallachBeth Capital LLC. The offering includes 10,156,250 shares of Common Stock (or pre-funded warrants) and warrants to purchase up to 15,234,375 shares of Common Stock. The combined public offering price is set at $0.32 per share with accompanying May 2025 Warrant. The offering is expected to close around May 7, 2025, subject to customary closing conditions. WallachBeth Capital is serving as the sole placement agent for this registered offering.

bioAffinity Technologies (NASDAQ: BIAF) has announced pricing for a $3.25 million securities offering. The offering consists of 10,156,250 shares of Common Stock (or pre-funded warrants) along with warrants to purchase up to 15,234,375 additional shares. The combined public offering price is set at $0.32 per share of common stock (or pre-funded warrant) with accompanying May 2025 Warrant. The offering is expected to close around May 7, 2025, with WallachBeth Capital, LLC serving as the sole placement agent.